Dr Francine I Friedman, MD | |
417 Hampton St, Camden, SC 29020-2809 | |
(803) 713-7443 | |
Not Available |
Full Name | Dr Francine I Friedman |
---|---|
Gender | Female |
Speciality | Psychiatry & Neurology - Psychiatry |
Location | 417 Hampton St, Camden, South Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1225145964 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Dr Francine I Friedman, MD 417 Hampton St, Camden, SC 29020-2809 Ph: (803) 713-7443 | Dr Francine I Friedman, MD 417 Hampton St, Camden, SC 29020-2809 Ph: (803) 713-7443 |
News Archive
Researchers at Columbia University Medical Center (CUMC) have identified the immune cells responsible for destroying hair follicles in people with alopecia areata, a common autoimmune disease that causes hair loss, and have tested an FDA-approved drug that eliminated these immune cells and restored hair growth in a small number of patients.
Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that Dr. Francisco Leon, CEO and Chief Medical Officer, will provide an oral presentation on an abstract related to the company's lead product candidate, AMG 714, at the 16th International Coeliac Disease Symposium, June 24, 2015, in Prague, Czech Republic.
Asian Indians are one of the fastest growing ethnic groups in the United States, and roughly half a million people of Indian ancestry live in California - more than any other state. Individuals from this group are strongly predisposed to obesity-related conditions such as diabetes and heart disease, due in large part to physical inactivity, diets low in fruit and vegetables, and insulin resistance.
Paratek Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic candidate, omadacycline (formerly known as PTK 0796), as a Qualified Infectious Disease Product (QIDP) for both intravenous (IV) and oral formulations in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
The brain is permanently exposed to new impressions. Even when sleeping, it does not rest and processes recent experiences.
› Verified 5 days ago